Healthcare shares split as trial failures meet commercial progress

Healthcare shares faced heavy selling this week. Cochlear (ASX:COH) fell 11.88% as it defended a class action linked to its FY26 profit forecast. EMVision Medical Devices (ASX:EMV) dropped 10.34%, even after receiving a A$4.3 million research and development tax refund. TrivarX (ASX:TRI) lost 9.09% after reporting a much larger annual loss and warning that it needs more money to continue.

Trial failures put survival first

Paradigm Biopharmaceuticals (ASX:PAR) entered voluntary administration after its Phase 3 trial missed the result needed to continue. Phase 3 is the large, late-stage test usually used to support an application for approval. Administrators will now assess the company’s debts, assets and possible restructuring options. The trial will not proceed as planned unless funding is found.

Cynata Therapeutics (ASX:CYP) reported a similar problem. Its Phase 2 and Phase 3 trials failed to show that its treatment worked. The company recorded a A$9.25 million loss, negative net assets and no remaining employees after year-end. A A$600,000 loan may extend its cash runway beyond FY2027, but the future of its Cymerus platform remains uncertain. Chimeric Therapeutics (ASX:CHM) also remains suspended while it negotiates with creditors and considers a possible recapitalisation.

Cash shortages spread across the sector

TrivarX has made its Stabl-Im magnetic resonance imaging platform its main project. However, its FY2026 loss rose to A$8.76 million, while year-end cash stood at A$2.44 million. The planned first human study remains subject to regulatory, ethics and operating approvals. The auditor said the company may not be able to continue without more money.

Ocean Sciences (ASX:OSS) increased seaweed revenue to A$3.444 million from A$235,990. Yet the group still recorded a A$1.612 million loss from continuing operations and used A$2.319 million in operating cash. Its auditor also questioned whether it can continue without new funding. The share price rose 7.69%, but investors still have to weigh sales growth against the company’s cash needs.

Sales and approvals offer some relief

Firebrick Pharma (ASX:FRE) gained 7.69% after approving a phased launch of Nasodine through US pharmacies. Online sales grew by more than 200% in FY26, and pharmacy groups representing about 700 stores have shown interest. No binding orders have been announced, so the next test is whether interest becomes paid sales.

Elsewhere, Memphasys (ASX:MEM) arranged a A$3.5 million advance to expand Felix production after repeat orders from overseas customers. The money carries 12.5% interest and may lead to a large increase in shares if converted. LTR Pharma (ASX:LTP) rose 5.62% after its nasal product reached peak blood levels in 10 minutes, compared with 60 minutes for an oral tablet. The result supports a planned US filing, but the product still needs testing in people with erectile dysfunction.

Regulatory progress produced mixed results. Vectus Biosystems (ASX:VBS) secured a meeting with the US Food and Drug Administration for its lung fibrosis drug candidate, but the stock fell 8.33%. After reopening at 0.125, it fell a further 12%, meaning the early buying did not hold. The FDA has not approved a clinical trial. EBR Systems (ASX:EBR) rose 6.12% after a factory inspection, although two issues must be fixed before final approval.

Patents and legal claims remain in play

Neuren (ASX:NEU) reported a possible US patent extension for trofinetide through March 2041. The patent has not yet formally issued. Mayne Pharma (ASX:MYX) agreed a potential 2032 generic entry date for IMVEXXY, subject to court approval. Cochlear’s class action is at an earlier stage, and the company denies the allegations.

Imagion Biosystems (ASX:IBX) cleared a central ethics review for its HER2 imaging trial. This allows site preparation and recruitment planning, but no patients have yet been enrolled. The milestone therefore provides no evidence yet about whether the treatment works or is safe.